Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019
- PMID: 34014329
- PMCID: PMC8138687
- DOI: 10.1001/jamanetworkopen.2021.4920
Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019
Abstract
This cross-sectional study uses direct pharmaceutical claims data from a commercial claims database to assess the use of 6 types of immunosuppressive drugs among commercially insured US adults in 2018 and 2019.
Conflict of interest statement
References
-
- US Centers for Disease Control and Prevention . Coronavirus disease 2019. 2021. Accessed February 12, 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-...
-
- Tomazini BM, Maia IS, Cavalcanti AB, et al. ; COALITION COVID-19 Brazil III Investigators . Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307-1316. doi: 10.1001/jama.2020.17021 - DOI - PMC - PubMed
-
- Gianfrancesco M, Hyrich KL, Al-Adely S, et al. ; COVID-19 Global Rheumatology Alliance . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
